The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients. A 12 Weeks Randomized Placebo-controlled Phase IV Study
Phase of Trial: Phase IV
Latest Information Update: 08 Jan 2017
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 02 Jan 2017 Status changed from recruiting to completed.
- 29 Jan 2016 Planned end date changed from 1 Sep 2015 to 1 Mar 2017, as reported by ClinicalTrials.gov.